ReviewExpert review of respiratory medicine2016
Advances in the treatment of virus-induced asthma.
Review in Expert review of respiratory medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.
- Effects of Fruit and Vegetable Consumption on Risk of Asthma, Wheezing and Immune Responses: A Systematic Review and Meta-Analysis.Nutrients · 2017Pooled it
- The Wiser Strategy of Using Beta-Agonists in Asthma: Mechanisms and Rationales.Allergy, asthma & immunology research · 2024Review
- Cullin5 drives experimental asthma exacerbations by modulating alveolar macrophage antiviral immunity.Nature communications · 2024Article
- Rhinovirus infection induces secretion of endothelin-1 from airway epithelial cells in both in vitro and in vivo models.Respiratory research · 2023Article
- Impact of Airway Virus in Severe Asthmatic Patients: A Pilot Study.Allergy, asthma & immunology research · 2023Article
- Epidemiology and Immunopathogenesis of Virus Associated Asthma Exacerbations.Journal of asthma and allergy · 2023Review
- IL-25 blockade augments antiviral immunity during respiratory virus infection.Communications biology · 2022Article
- Viral Infection and Respiratory Exacerbation in Children: Results from a Local German Pediatric Exacerbation Cohort.Viruses · 2022Article
- Innate Immune Evasion by Human Respiratory RNA Viruses.Journal of innate immunity · 2020Review
- The manufacturing of human viral challenge agents for use in clinical studies to accelerate the drug development process.BMC research notes · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Viral exacerbations continue to represent the major burden in terms of morbidity, mortality and health care costs associated with asthma. Those at greatest risk for acute asthma are those with more severe airways disease and poor asthma control. It is this group with established asthma in whom acute exacerbations triggered by virus infections remain a serious cause of increased morbidity. A range of novel therapies are emerging to treat asthma and in particular target this group with poor disease control, and in most cases their efficacy is now being judged by their ability to reduce the frequency of acute exacerbations. Critical for the development of new treatment approaches is an improved understanding of virus-host interaction in the context of the asthmatic airway. This requires research into the virology of the disease in physiological models in conjunction with detailed phenotypic characterisation of asthma patients to identify targets amenable to therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.